Biotage AB (STU:PQX1) Debt-to-Asset : 0.08 (As of Mar. 2024)

View and export this data going back to 2007. Start your Free Trial

What is Biotage AB Debt-to-Asset?

Biotage AB's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was €2.9 Mil. Biotage AB's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was €32.4 Mil. Biotage AB's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Mar. 2024 was €454.8 Mil. Biotage AB's debt to asset for the quarter that ended in Mar. 2024 was 0.08.

Biotage AB Debt-to-Asset Historical Data

The historical data trend for Biotage AB's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biotage AB Debt-to-Asset Chart

Biotage AB Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Asset

Get a 7-Day Free Trial

0.18

0.11

0.10

0.09

0.05

Biotage AB Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Asset	Get a 7-Day Free Trial															0.09	0.08	0.08	0.05	0.08

Competitive Comparison of Biotage AB's Debt-to-Asset

For the Medical Instruments & Supplies subindustry, Biotage AB's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Biotage AB's Debt-to-Asset Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Biotage AB's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Biotage AB's Debt-to-Asset falls into.

Biotage AB Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Biotage AB's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(2.95	+	20.204)	/	440.817
	=	0.05

Biotage AB's Debt-to-Asset for the quarter that ended in Mar. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(2.916	+	32.43)	/	454.817
	=	0.08

Biotage AB (STU:PQX1) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Biotage AB Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Biotage AB's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Biotage AB (STU:PQX1) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Biotage AB (STU:PQX1) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

BIOT:Sweden 0GRP:UK

Address

Vimpelgatan 5, Box 8, Uppsala, SWE, 751 03

Website

https://www.biotage.com

Biotage AB provides separation technology and solutions for analytical and organic chemistry from research to commercial analytical laboratories and industrial applications. Its customers span a broad range of market segments including pharmaceutical, biotech, diagnostic, contract research, and contract manufacturers as well as clinical, forensic, and academic laboratories in addition to organizations focused on food safety, clean water, and environmental sustainability. It serves three geographic markets: The Americas, APAC (Asia-Pacific,) and EMEA (Europe, Middle East & Africa). The company's product areas include Small Molecules & Synthetic Therapeutics, Biologics & Advanced Therapeutics, Scale-Up, Diagnostics, Analytical Testing, and Water & Environmental Testing.

Biotage AB (STU:PQX1) Headlines

No Headlines